Humbert O., Riedinger J.M., Vrigneaud J.M., Kanoun S., Digay-Cochet I., Berriolo-Riedinger A., Toubeau M., Depardon E., Lasserre M., Tisserand S.,Fumoleau P., Brunotte F., Cochet A. 18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer. J Nucl Med. 2016 Apr 21.
http://jnm.snmjournals.org/content/early/2016/04/21/jnumed.116.172759.abstract
Humbert O., Cochet A., Coudert B., Berriolo-Riedinger A., Kanoun S., Brunotte F., Fumoleau P. Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer. Oncologist. 2015, 20: 94-104.
http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=25561512
Humbert O., Riedinger J. M., Charon-Barra C., Berriolo-Riedinger A., Desmoulins I., Lorgis V., Kanoun S., Coutant C., Fumoleau P., Cochet A., Brunotte F. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin. Cancer Res. 2015 Jun 30.
http://clincancerres.aacrjournals.org/content/21/24/5460.long
Maurizi L., Papa A.L., Dumont L., Bouyer F., Walker P., Vandroux D., Millot N. Influence of Surface Charge and Polymer Coating on Internalization and Biodistribution of Polyethylene Glycol-Modified Iron Oxide Nanoparticles. J Biomed Nanotechnol. 2015, 11(1): 126-36.
http://www.ingentaconnect.com/content/asp/jbn/2015/00000011/00000001/art00009
Bernhard Y., Collin B., Decreau R. A. Inter/Intramolecular Cherenkov Radiation Energy Transfer (CRET) From a Fluorophore With a Built-in Radionuclide. Chem. Commun. (Camb. ) 2014, 50: 6711-6713.
http://pubs.rsc.org/en/Content/ArticleLanding/2014/CC/c4cc01690d#!divAbstract
Humbert O., Berriolo-Riedinger A., Cochet A., Gauthier M., Charon-Barra C., Guiu S., Desmoulins I., Toubeau M., Dygai-Cochet I., Coutant C., Fumoleau P., Brunotte F. Prognostic Relevance at 5 Years of the Early Monitoring of Neoadjuvant Chemotherapy Using (18)F-FDG PET in Luminal HER2-Negative Breast Cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014, 41: 416-427.
http://link.springer.com/article/10.1007%2Fs00259-013-2616-3
Humbert O., Cochet A., Riedinger J. M., Berriolo-Riedinger A., Arnould L., Coudert B., Desmoulins I., Toubeau M., Dygai-Cochet I., Guiu S., Coutant C., Fumoleau P., Brunotte F. HER2-Positive Breast Cancer: 18F-FDG PET for Early Prediction of Response to Trastuzumab Plus Taxane-Based Neoadjuvant Chemotherapy. Eur. J. Nucl. Med. Mol. Imaging 2014, 41: 1525-1533.
http://link.springer.com/article/10.1007%2Fs00259-014-2739-1
Cochet A., Dygai-Cochet I., Riedinger J. M., Humbert O., Berriolo-Riedinger A., Toubeau M., Guiu S., Coutant C., Coudert B., Fumoleau P., Brunotte F. 18F-FDG PET/CT Provides Powerful Prognostic Stratification in the Primary Staging of Large Breast Cancer When Compared With Conventional Explorations. Eur. J. Nucl. Med. Mol. Imaging. 2014, 41: 428-437.
http://dx.doi.org/10.1007/s00259-013-2595-4
Walker P, Provent P, Tizon X, Créhange G, Duchamp O, Brunotte F, Genne P: In-vivo metabolic characterization of healthy prostate and orthotopic prostate cancer in rats using proton magnetic resonance spectroscopy at 4.7 T. Acta Radiol. 2013, 54(1): 121-6.
http://acr.sagepub.com/content/54/1/121.abstract
Cochet A., Pigeonnat S., Khoury B., Vrigneaud J. M., Touzery C., Berriolo-Riedinger A., Dygai-Cochet I., Toubeau M., Humbert O., Coudert B., Fumoleau P., Arnould L., Brunotte F. Evaluation of Breast Tumor Blood Flow With Dynamic First-Pass 18F-FDG PET/CT: Comparison With Angiogenesis Markers and Prognostic Factors. J. Nucl. Med. 2012, 53: 512-520.
http://jnm.snmjournals.org/content/53/4/512.long
Humbert O., Berriolo-Riedinger A., Riedinger J. M., Coudert B., Arnould L., Cochet A., Loustalot C., Fumoleau P., Brunotte F. Changes in 18F-FDG Tumor Metabolism After a First Course of Neoadjuvant Chemotherapy in Breast Cancer: Influence of Tumor Subtypes. Ann. Oncol. 2012, 23: 2572-2577.
http://annonc.oxfordjournals.org/content/23/10/2572.long
Moreau M., Raguin O., Vrigneaud J. M., Collin B., Bernhard C., Tizon X., Boschetti F., Duchamp O., Brunotte F., Denat F. DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes. Bioconjug. Chem. 2012, 23: 1181-1188.
http://pubs.acs.org/doi/abs/10.1021/bc200680x
Cochet A., Quilichini G., Dygai-Cochet I., Touzery C., Toubeau M., Berriolo-Riedinger A., Coudert B., Cottin Y., Fumoleau P., Brunotte F. Baseline Diastolic Dysfunction As a Predictive Factor of Trastuzumab-Mediated Cardiotoxicity After Adjuvant Anthracycline Therapy in Breast Cancer. Breast Cancer Res. Treat. 2011, 130 : 845-854.
http://link.springer.com/article/10.1007%2Fs10549-011-1714-9
Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P. Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year. Int J Radiat Oncol Biol Phys. 2011, 81(4): e407-13.
http://www.redjournal.org/article/S0360-3016(11)00465-2/abstract
